ArticleClinical ophthalmology (Auckland, N.Z.)2025
Profile and Management Outcomes of Neurotrophic Keratitis at A Tertiary Eye Hospital in Saudi Arabia: A Cohort Study.
Article in Clinical ophthalmology (Auckland, N.Z.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Management of Dry Eye Disease Pre- and Post-Cataract Surgery: A Personalized Approach.Journal of personalized medicine · 2026Review
- Corneal neurotization for neurotrophic keratopathy: a case report of two patients from different age groups.Frontiers in ophthalmology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To evaluate the neurotrophic keratitis (NK) profile, management outcomes, and determinants at a tertiary eye hospital in Saudi Arabia. Methods: This historical cohort comprised patients with the ICD-10 code of H16.239 who presented and were treated from 2014 to 2024. The classification of NK based on Mackie's criteria; NK was classified into stages 1-3. Demographic data, NK etiology, and both medical and surgical therapeutic interventions were analyzed. We correlated these outcomes with the etiology, stages, and treatment modalities. Results: The cohort had 94 eyes of 80 NK patients in stage 1 (6, 6%), stage 2 (69, 74%), and stage 3 (19, 20%). Seventy-Three (77.7%) eyes showed reduced corneal sensation, 14 (15%) eyes showed intact corneal sensation, and 7 (7.4%) eyes showed no discernible corneal sensation. Herpes zoster (22.5%) was the most common infectious etiology followed by herpes simplex (2.5%). Trigeminal palsy was observed in 24 (30%) eyes. Iatrogenic NK was present in 12 (15%) eyes. Decreased vision (88.1%), redness of the eyes (47.6%), and swollen lids (34.5%) were the main symptoms. The most frequently performed procedures included amniotic membrane transplantation (AMT) (45.7%), tarsorrhaphy (36.2%), and corneal gluing (17%). At the last follow-up after management, the Best Corrected Visual Acuity (BCVA) was 1.5 logMAR in eyes affected by NK. At presentation (78.2%) and after treatment (38.2%), eyes with NK had severe visual impairment (SVI). Conclusion: The management of NK presents significant challenges but offers potential rewards, as it facilitates ocular preservation and may enable visual restoration following initial therapeutic intervention.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.